Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-17

Study Completion Date

2025-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries. A promising strategy aimed at blocking the circulation of arboviruses is to release Aedes aegypti mosquitoes carrying the endosymbiotic bacterium Wolbachia. In 2019, the Wolbachia strategy was implemented in Nouméa as part of the World Mosquito Program. This intervention will modify the epidemiological profile of arboviruses in New Caledonia.

Epidemiological surveillance of arboviruses requires molecular characterization of the virus contained in the serum obtained from the blood collected from patients. This molecular characterization by RNA isolation techniques, RT-qPCR monitoring and sequencing allows the construction of phylogenetic trees.

In the context of the implementation of the World Mosquito Program in Nouméa, the investigators plan to follow the molecular evolution of arboviruses, over the period preceding the releases of mosquitoes carrying Wolbachia (from 1995 to 2019) then over a period of 5 years. following the releases.

At the same time, the virus can be isolated by cell culture techniques and in vitro infections, allowing its study in vitro in cells or in vivo in mosquitoes. This study allows us to measure the impact of the Wolbachia strategy on the evolution of the virus's ability to replicate in cells in the presence of Wolbachia and to be transmitted by the mosquito.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

NCT04619823

Arbovirus Infections Zika Dengue +1 more

RECRUITING NA

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

NCT03631719

Dengue Chikungunya Virus Infection Zika Virus Infection

COMPLETED

World Mosquito Program Noumea - Human Sample Component

NCT03552094

Arbovirus Infections

UNKNOWN

Sero-epidemiology of Priority Arboviruses in French Guiana

NCT03210363

Arbovirus Infections

COMPLETED NA

Impact of Project Wolbachia - Singapore on Dengue Incidence

NCT05505682

Dengue

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Collection of blood samples from patients with arbovirus infection

This study is a non-interventional study with retrospective part.

This study will improve :

* the assessment of the molecular evolution of arboviruses in the period preceding the implementation of the Wolbachia strategy
* the knowledge of the impact of Wolbachia on the diversity and molecular evolution of arboviruses
* the understanding of arbovirus transmission and replication mechanisms in the presence of Wolbachia

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arbovirus Infections Dengue Zika Chikungunya

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Appearance of clinical signs suggestive of an infection with an arbovirus in the 7 days preceding the blood sample,
* Diagnostic confirmation by RT-qPCR of mono-infection with dengue virus or another arbovirus.
* Patients or their representative (s) informed of the possible secondary use for research purposes of the samples initially taken for diagnostic purposes and their derivatives, and who have not since expressed their opposition to the secondary use of the samples diagnostics or their derivatives for research,

Exclusion Criteria

* Documented opposition from a patient or his representative (s)
* Previously established viral load too low.
* Sample obtained from a sample taken more than 7 days after the appearance of clinical signs of infection.

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No